李 茜綜述，唐 紅審校

(四川大學華西醫(yī)院心血管內(nèi)科，四川 成都 610041)

綜述

超聲心動圖對系統(tǒng)性紅斑狼瘡心臟并發(fā)癥的評估

李 茜綜述，唐 紅*審校

(四川大學華西醫(yī)院心血管內(nèi)科，四川 成都 610041)

系統(tǒng)性紅斑狼瘡(SLE)是一種累及全身多系統(tǒng)、多器官的復雜自身免疫性彌漫性結締組織病，心血管并發(fā)癥已成為其主要的死亡原因之一。SLE合并心血管并發(fā)癥的診斷及評估多依賴于影像學檢查。超聲心動圖無創(chuàng)、簡便、可靠，是心臟結構和功能評估的有效手段。本文對超聲心動圖在SLE患者心臟病變評估中的應用做一綜述。

紅斑狼瘡，系統(tǒng)性；心血管并發(fā)癥；超聲心動描記術

系統(tǒng)性紅斑狼瘡(systemic lupus erythematosus， SLE)是一種累及全身多個臟器的復雜自身免疫性彌漫性結締組織病，以免疫性炎癥為典型表現(xiàn)，主要累及心血管、腎臟、神經(jīng)精神系統(tǒng)、血液系統(tǒng)、肺、消化系統(tǒng)、眼及外分泌腺。SLE合并心血管并發(fā)癥的死亡率逐年升高，已成為SLE患者主要的死亡原因之一[1]。SLE患者發(fā)生心血管疾病(cardiovascular disease, CVD)的概率是正常人群的7倍[2]。SLE合并CVD的高發(fā)病率及高死亡率的原因與加速的動脈硬化過程相關[3]，而其發(fā)生也是CVD的傳統(tǒng)危險因素及狼瘡特有的危險因素交互作用的結果[2-4]。一方面，SLE本身的免疫性炎癥可致血小板的不穩(wěn)定；另一方面，SLE患者有高發(fā)的傳統(tǒng)CVD危險因素，如高血壓、脂代謝紊亂[5]、長期激素治療所致的糖耐量降低[6]。此外，合并腎臟損害和免疫抑制療法可加重心血管損害[7-8]。

SLE患者心臟病變包括冠狀動脈性心臟病、心肌病變、瓣膜病變、心包炎及肺動脈高壓(pulmonary artery hypertension, PAH)，對其診斷和評估多依賴于影像學檢查。超聲心動圖因其具有無創(chuàng)、簡便、可靠的優(yōu)點，在其中發(fā)揮著重要的作用。

常規(guī)超聲心動圖檢查包括M型超聲、二維超聲、頻譜多普勒、彩色多普勒、組織多普勒及經(jīng)食管超聲心動圖(transesophageal echocardiography, TEE)等。各種超聲技術臨床常聯(lián)合應用，互為補充，被廣泛應用于心臟疾病的診斷及鑒別診斷。此外，實時三維超聲心動圖(real-time three-dimensional echocardiography, RT-3DE)、斑點追蹤技術等也在心臟疾病的診治中發(fā)揮著重要作用。本文主要對超聲心動圖在SLE患者心臟病變評估中的應用進行綜述。

1 冠狀動脈性心臟病

SLE的免疫性炎癥可發(fā)生于冠狀動脈，導致冠狀動脈內(nèi)皮細胞變性壞死，局部內(nèi)膜增生，管腔灶性狹窄，局部組織壞死及血栓形成，最終導致冠狀動脈狹窄，輕者可致心絞痛發(fā)生，重癥者可致心肌梗死。相對于正常人群，SLE患者更易發(fā)生冠狀動脈性心臟病[7]，至少13%的SLE患者有心絞痛、心肌梗死等冠狀動脈受累表現(xiàn)[9]。而更多亞臨床患者缺乏特異性表現(xiàn)，尤其是年輕患者。因其他原因死亡的SLE患者中約50%均有冠狀動脈受累[10]。

通過M型超聲心動圖可獲取室壁的運動曲線。觀察室壁厚度、收縮期增厚率及運動幅度可判斷取樣部位心肌是否缺血。利用二維超聲心動圖可直接觀察冠狀動脈走行及內(nèi)徑，但由于聲窗的影響，僅能顯示部分冠狀動脈血管。通過室壁形態(tài)改變(室壁變薄、纖維化和室壁瘤形成)和室壁運動異常(室壁運動幅度降低、消失，收縮期室壁增厚率降低或消失，甚至出現(xiàn)反向運動)判斷受累心肌，是診斷冠心病的重要手段。對于穩(wěn)定型心絞痛的患者，運動負荷檢查為診斷及評估疾病嚴重程度的重要方法，可用于診斷初發(fā)穩(wěn)定型心絞痛[11]。通過超聲心動圖的冠狀動脈血流成像可評估冠狀動脈血流，為診斷冠心病提供依據(jù)[12]。

2 心肌病變

尸體檢查發(fā)現(xiàn)SLE心肌病變的發(fā)生率約40%～70%，但因心功能受損而出現(xiàn)相關臨床癥狀的患者僅占10%[13]，部分左心室射血分數(shù)(left ventricular ejection fraction， LVEF)正常的患者其心肌運動已出現(xiàn)異常。SLE心肌病變可導致心力衰竭[14]。因此，早期評估SLE患者心肌受累情況對臨床診療及預后評估具有重要意義。利用超聲心動圖不僅可對SLE患者心功能下降進行定量評估，通過斑點追蹤等超聲新技術還可發(fā)現(xiàn)亞臨床狀態(tài)下心肌運動異常。

2.1 左心功能評估 通過脈沖多普勒及組織多普勒對二尖瓣及肺靜脈血流、二尖瓣瓣環(huán)運動、肺動脈壓力等進行評估，可評價心室舒張功能。應用組織多普勒可直接評價心肌運動，較脈沖多普勒的間接評價更為準確[15]。有學者[16]評估LVEF正常的SLE患者心臟舒張功能，發(fā)現(xiàn)45.3%的患者出現(xiàn)舒張功能受損，其危險因素包括病程、是否合并抗磷脂綜合征(antiphospholipid syndrome, APS)、高血壓。Shang等[17]發(fā)現(xiàn)左心室舒張功能與損傷因素相關。Roldan等[18]采用TEE獲得主動脈壓力-應變彈性系數(shù)對主動脈彈性進行評價，發(fā)現(xiàn)該指標與SLE患者心臟舒張功能呈負相關。

除舒張功能受損外，部分SLE患者還伴收縮功能的亞臨床改變。組織多普勒、二維及三維斑點追蹤技術的應用可實現(xiàn)對心肌收縮功能的評估。組織多普勒操作簡單、重復性好，被廣泛應用于心臟功能減退的評估，但受角度依賴性的限制和周圍組織的影響，準確性有所下降。二維應變分析不受角度依賴性的限制，并可評估心肌在多個方向的應變。Bulut等[19]應用Simpson雙平面法及二維斑點追蹤技術，發(fā)現(xiàn)在LVEF正常的情況下，心肌已出現(xiàn)總體應變的下降，而僅在SLE極度活躍時才出現(xiàn)心室扭轉(zhuǎn)的下降。三維斑點追蹤技術可提供LVEF、三維左心室質(zhì)量、球形指數(shù)以及三維應變等定量指標。Huang等[20]應用三維斑點追蹤技術對LVEF正常的SLE患者進行研究，發(fā)現(xiàn)其整體縱向、環(huán)向及徑向應變較正常對照組均有所減低，重度活動性SLE患者中各項應變的下降更明顯。

左心房在維持正常的心輸出量中有重要的作用，LVEF正常的SLE患者多已存在舒張功能的受損，此時左心房常有容量負荷的增加。Dai等[21]研究報道，LVEF正常的SLE患者存在左心房功能受損，且主要與SLE活躍程度相關。Li等[22]采用RE-3DE技術研究發(fā)現(xiàn)SLE患者左心房容積較正常對照組有所增加，隨SLE損傷指數(shù)(rheumatology damage index, SDI)的增加，左心房排空分數(shù)減低。

亞臨床狀態(tài)下的SLE患者已存在左心功能受損，SLE病程及活動性為其主要危險因素，對于病程長、疾病活動性大的患者應進行密切的心功能隨訪。

2.2 右心室功能評估 SLE可引起右心室受累。此外，SLE常并發(fā)PAH，可加重右心室功能損害。研究[23-26]發(fā)現(xiàn)SLE合并PAH患者的右心室功能降低。

超聲心動圖評估右心室功能的指標包括三尖瓣前瓣環(huán)收縮期運動幅度(tricuspid annular plane systolic excursion, TAPSE)、Tei指數(shù)、組織多普勒三尖瓣前瓣環(huán)收縮期S峰(tissue Doppler systolic S wave, TDI-S)、斑點追蹤技術、三維右心室EF測值等。Leal等[27]研究發(fā)現(xiàn)SLE患兒右心室總體長軸應變(global peak longitudinal systolic strain, PLSS)及TAPSE均較正常對照組降低,且這兩個指標呈現(xiàn)出較好的相關性。由于右心室形態(tài)不規(guī)則，常規(guī)LVEF測量的方法，如M型超聲及Simpson雙平面法，并不適用于對右心室的評估[28]。RT-3DE可用以評價右心室功能，其準確性已被證實[29-30]。但目前關于RT-3DE技術評估SLE患者右心室功能的研究尚少。

3 瓣膜病變

SLE患者血漿中的免疫復合物及補體沉積于心瓣膜即可導致瓣膜損害，主要表現(xiàn)為瓣膜增厚(纖維化或鈣化)、瓣葉穿孔、瓣膜狹窄、瓣膜反流和疣狀心內(nèi)膜炎，可發(fā)生于所有瓣膜，但以二尖瓣及主動脈瓣最為常見[31]。超聲心動圖可用于評估瓣膜形態(tài)及功能改變，觀察瓣膜形態(tài)、贅生物的附著位置、大小、數(shù)目、形態(tài)[32]。TEE較常規(guī)經(jīng)胸超聲心動圖診斷疣狀心內(nèi)膜炎更具優(yōu)勢[33]，但對疣狀心內(nèi)膜炎和感染性心內(nèi)膜炎的區(qū)分仍較困難[34]。另外，超聲隨訪研究[35]發(fā)現(xiàn)SLE/APS及其病程是發(fā)生瓣膜疾病的獨立危險因素，且抗凝治療不能阻止疾病進程。

4 心包炎

約40%的SLE患者存在急慢性心包損害，但多數(shù)患者無癥狀[36]。心臟壓塞，縮窄性心包炎、化膿性心包炎等嚴重并發(fā)癥較為罕見，而心包積液則較為常見。采用二維超聲心動圖可定量測量心包積液深度，觀察有無心包增厚，為臨床診療提供參考依據(jù)。

5 PAH

PAH定義為靜息時平均肺動脈壓(mean pulmonary arterial pressure, MPAP)≥25 mmHg，肺動脈楔壓(pulmonary artery wedge pressure, PAWP)或左心室舒張末期壓力≤15 mmHg及持續(xù)增加的肺血管阻力(pulmonary vascular resistance, PVR)[37]。SLE相關性PAH的發(fā)病機制主要是炎細胞、自身抗體等浸潤肺小動脈壁，產(chǎn)生PVR，最終導致PAH[38]。SLE合并PAH的概率為0.5%～17.5%[39]。

目前診斷PAH的金標準為心導管檢查，但超聲心動圖是篩查PAH的重要手段。常用方法是通過連續(xù)多普勒測量三尖瓣反流壓差估算肺動脈收縮壓[40]。通過二維超聲心動圖可觀察PAH引起的心臟結構改變，如右心增大、肺動脈增寬、下腔靜脈塌陷率減低等。

綜上所述，SLE患者心臟結構及功能均存在損害。超聲心動圖作為一種無創(chuàng)、便捷的心臟結構及功能評估方法，對SLE患者的心臟結構及功能評估起著重要作用。

[1] Knight JS, Kaplan MJ. Cardiovascular disease in lupus: Insights and updates. Curr Opin Rheumatol, 2013,25(5):597-605.

[2] Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum, 2001,44(10):2331-2337.

[3] Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med， 2003,349(25):2399-2406.

[4] Bessant R, Duncan RG, Swanton J, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum, 2006,55(6):892-899.

[5] MacGregor AJ, Dhillon VB, Binder A, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis, 1992,51(2):152-155.

[6] Karp I, Michal A, Fortin PR, et al. Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum, 2008,59(2):169-175.

[7] Skaggs BJ, Hahn BH, Mcmahon M. Accelerated atherosclerosis in patients with SLE—mechanisms and management. Nat Rev Rheumatol, 2012,8(4):214-223.

[8] Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol, 2007,157(5):545-559.

[9] Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology, 2000,39(3):238-244.

[10] Abu-shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus. Results from a single center. Ⅰ. Causes of death. J Rheumatol, 1995,22(7):1259-1264.

[11] Zacharias K, Ahmed A, Shah BN, et al. Relative clinical and economic impact of exercise echocardiography vs. exercise electrocardiography, as first line investigation in patients without known coronary artery disease and new stable angina: A randomized prospective study. Eur Heart J Cardiovasc Imaging, 2016 Mar 24. [Epub ahead of print].

[12] Li Y, Fang F, Ma N, et al. Feasibility study of transthoracic echocardiography for coronary slow flow phenomenon evaluation: Validation by coronary angiography. Microcirculation, 2016,23(4):277-282.

[13] Sasson Z, Rasooly Y, Chow CW, et al. Impairment of left ventricular diastolic function in systemic lupus erythematosus. Am J Cardiol, 1992,69(19):1629-1634.

[14] Sophie M, Costas S, Costas B, et al. Myocarditis as a precipitating factor for heart failure: Evaluation and 1-year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy. Eur J Heart Fail, 2011,13(8):830-837.

[15] Cacciapuoti F, Galzerano D, Capogrosso P, et al. Impairment of left ventricular function in systemic lupus erythematosus evaluated by measuring myocardial performance index with tissue Doppler echocardiography. Echocardiography, 2005,22(4):315-319.

[16] Gusetu G, Pop D, Pamfil C, et al. Subclinical myocardial impairment in SLE: Insights from novel ultrasound techniques and clinical determinants. Med Ultrasond, 2016,18(1):47.

[17] Shang Q, Yip GW, Tam LS, et al. SLICC/ACR damage index independently associated with left ventricular diastolic dysfunction in patients with systemic lupus erythematosus. Lupus, 2012,21(10):1057-1062.

[18] Roldan CA, Alomari IB, Khaled A, et al. Aortic stiffness is associated with left ventricular diastolic dysfunction in systemic lupus erythematosus: A controlled transesophageal echocardiographic study. Clin Cardiol, 2014,37(2):83-90.

[19] Bulut M, Acar RD, Acar, et al. Evaluation of torsion and twist mechanics of the left ventricle in patients with systemic lupus erythematosus. Anatol J Cardiol， 2016，16(6):434-439.

[20] Huang BT, Yao HM, Huang H. Left ventricular remodeling and dysfunction in systemic lupus erythematosus: A three-dimensional speckle tracking study. Echocardiography, 2014,31(9):1085-1094.

[21] Dai M, Li KL, Qian DJ, et al. Evaluation of left atrial function by speckle tracking echocardiography in patients with systemic lupus erythematosus. Lupus, 2015,42(2):196-201.

[22] Li K, Wang R, Dai M, et al. Evaluation of left atrial function by real-time 3-D echocardiography in patients with systemic lupus erythematosus. J Rheumatol, 2014,42(2):196-201.

[23] Plazak W, Kopec G, Tomkiewicz-Pajak L, et al. Heart structure and function in patients with generalized autoimmune diseases: Echocardiography with tissue Doppler study. Acta Cardiol, 2011,66(2):159-165.

[24] Duman D, Masatliolu S, Demirtun? R, et al. Increased pulmonary artery stiffness and its relation to right ventricular function in patients with systemic lupus erythematosus. Turk Kardiyol Dern Ars, 2008,36(2):82-89.

[25] 李華,唐立,胡劼,等.單心動周期實時三維超聲心動圖評價肺動脈高壓患者右室整體功能的研究.臨床心血管病雜志,2014(12):1036-1037.

[26] 林薿,李春梅,尹立雪,等.實時三維超聲心動圖評價系統(tǒng)性紅斑狼瘡并發(fā)肺動脈高壓患者右心功能.中國醫(yī)學影像技術,2015,31(9):1331-1335.

[27] Leal GN, Silva KF, Lianza AC, et al. Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: Insights from two-dimensional speckle-tracking echocardiography. Lupus, 2014,24(6):613-620.

[28] Lawrence GR, Wyman WL, Jonathan A, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography. J Am Soc Echocardiogr 2010，23(7):685-713.

[29] Fei HW, Wang XF, Xie MX, et al. Validation of real-time three-dimensional echocardiography for quantifying left and right ventricular volumes: An experimental study. Chin Med J (Engl), 2004,117(5):695-699.

[30] Grison A, Maschietto NE, Stellin G, et al. Three-dimensional echocardiographic evaluation of right ventricular volume and function in pediatric patients: Validation of the technique. J Am Soc Echocardiogr, 2007,20(8):921-929.

[31] Maksimowicz-Mckinnon K, Mandell BF. Understanding valvular heart disease in patients with systemic autoimmune diseases. Cleve Clin J Med, 2004,71(11):881-885.

[32] Bruun NE, Habib G, Thuny F, et al. Cardiac imaging in infectious endocarditis. Eur Heart J, 2014,35(10):624-632.

[33] Roldan CA, Kirsten T, Leonardo M, et al. Libman-Sacks endocarditis: Detection, characterization, and clinical correlates by three-dimensional transesophageal echocardiography. J Am Soc Echocardiogr, 2015,28(7):306-311.

[34] Buppajarntham S, Satitthummanid S, Chantranuwatana P, et al. Aortic valve papillary fibroelastoma associated with severe aortic regurgitation: A comprehensive assessmentwith 2- and 3-dimensional transesophageal echocardiography. J Am Coll Cardiol, 2012,60(23):e41.

[35] Kampolis C, Tektonidou M, Moyssakis I, et al. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study. Semin Arthritis Rheum, 2014,43(4):558-565.

[36] Tincani A, Rebaioli CB, Taglietti M, et al. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford), 2006,45(Suppl 4):iv8-13.

[37] McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol, 2009,53(17):1573-1619.

[38] Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J, 2014,44(4):963-972.

[39] Arnaud L, Agard C, Haroche J, et al. Pulmonary arterial hypertension in systemic lupus erythematosus. Rev Med Interne, 2011,32(11):689-697.

[40] Fo?s E, Le GV, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: Retrospective analysis of 93 patients. Clin Exp Rheumatol, 2010,28(6):836-841.

Assessment of cardiovascular complications in patients with systemic lupus erythematosus by echocardiography

LIXi,TANGHong*

(DepartmentofCardiology,WestChinaHospitalofSichuanUniversity，Chengdu610041，China)

Systemic lupus erythematosus (SLE) is a kind of complex autoimmune connective tissue disease involving multi-organ and multiple systems. And the cardiovascular complication is a major cause of mortality in SLE patients. The diagnosis and evaluation depend on imaging. As a non-invasive, simplicity and repeatability method， echocardiography plays a vital role in evaluating heart structure and function. The application of echocardiography in the SLE with cardiovascular complications were reviewed in this article.

Lupus erythematosus, systemic; Cardiovascular complications; Echocardiography

李茜(1990—)，女，四川巴中人，碩士，醫(yī)師。研究方向：超聲心動圖。E-mail: plor@qq.com

唐紅，四川大學華西醫(yī)院心血管內(nèi)科，610041。

E-mail： hxyyth@qq.com

2016-07-15

2017-01-08

10.13929/j.1003-3289.201607068

R593.24； R540.45

A

1003-3289(2017)04-0624-04